License, Collaboration and Other Significant Agreements - Janssen Pharmaceutica NV Research and License Agreement (Details) - Development And Commercialize Research And License Agreement $ in Millions	Feb. 09, 2017 USD ($) shares
Janssen Pharmaceutica NV
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Collaborative arrangement, term	3 years
Upfront payment made in cash	$ 1.0
Potential milestone revenue from developmental milestones (up to)	16.5
Potential milestone revenue from commercial milestones (up to)	$ 215.0
Johnson & Johnson Innovation
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Warrant to purchase common stock (in shares) \| shares	509,611

Collaborative Arrangement, Term

No definition available.

Name:	akba_CollaborativeArrangementTerm
Namespace Prefix:	akba_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

Potential payment for achievement of specified commercial milestones.

+ References

No definition available.

+ Details

Name:	akba_PotentialPaymentForAchievementOfSpecifiedCommercialMilestones
Namespace Prefix:	akba_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Potential payment for achievement of specified development milestones.

+ References

No definition available.

+ Details

Name:	akba_PotentialPaymentForAchievementOfSpecifiedDevelopmentMilestones
Namespace Prefix:	akba_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Upfront payment paid in cash.

+ References

No definition available.

+ Details

Name:	akba_UpfrontPaymentPaidInCash
Namespace Prefix:	akba_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=123467817&loc=d3e21475-112644

+ Details

Name:	us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
Namespace Prefix:	us-gaap_
Data Type:	xbrli:sharesItemType
Balance Type:	na
Period Type:	instant

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

No definition available.

+ Details

Name:	us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Details

Name:	srt_CounterpartyNameAxis=akba_JanssenPharmaceuticaNVMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=akba_DevelopmentAndCommercializeResearchAndLicenseAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_CounterpartyNameAxis=akba_JohnsonAndJohnsonInnovationMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type: